HPR253 Drug development and launch timeline analysis across 6 high-income countries:from pivotal trial to HTA

Zaitceva, V; Tan, I; Mills, M.; and Kanavos, P.

(2024) HPR253 Drug development and launch timeline analysis across 6 high-income countries:from pivotal trial to HTA. Value in Health, 27 (12, Supplement). S323 - S323. ISSN 1098-3015

Copy

This study aims to (1) investigate the time intervals between key steps in drug development and launch: pivotal clinical trial, regulatory approval, and HTA decision and (2) explore the impact of drug characteristics, clinical trial design, regulatory pathways, and firm characteristics on these timelines.

Item Type	Article
Keywords	AAM not requested
Departments	Health Policy
DOI	10.1016/j.jval.2024.10.1677
Date Deposited	18 Mar 2025 09:21
URI	https://researchonline.lse.ac.uk/id/eprint/127581

Explore Further

Full text not available from this repository.

Atom

BibTeX

OpenURL ContextObject in Span

OpenURL ContextObject

Dublin Core

MPEG-21 DIDL

Data Cite XML

EndNote

HTML Citation

METS

MODS

RIOXX2 XML

Reference Manager

Refer

ASCII Citation

Export

Downloads